Results 241 to 250 of about 166,368 (358)

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS). [PDF]

Curr Oncol
Berg T, Salter B, Radford M, Chen HTT, Leber B.   +4 more
europepmc   +1 more source

Cystatin C‐based eGFR better predicts renal vancomycin clearance than creatinine‐based eGFR in patients with allogeneic stem cell transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Knowledge of the glomerular filtration rate (GFR) is mandatory when dosing renally eliminated drugs such as vancomycin. In clinical practice, different biomarkers and various equations are used to estimate GFR (eGFR), resulting in varying estimates.
Eva‐Maria A. Wansing, Sebastian G. Wicha, Peter Bannas, Alexander Heitkamp, Adrin Dadkhah, Nicolaus M. Kröger, Isabel Molwitz, Claudia Langebrake   +7 more
wiley   +1 more source

Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation. [PDF]

Chin J Cancer Res
Chen Y, Li S, Zhao X, Chang Y.
europepmc   +1 more source

Donor pretreatment with FLT-3 ligand augments anti-donor CTL, NK and LAK cell activities within liver allografts and alters the pattern of intragraft apoptotic activity [PDF]

, 1998
Chambers, FG, Fu, F, Fung, JJ, Li, W, Lu, L, Pan, F, Qian, S, Starzl, TE, Steptoe, RJ, Thomson, AW   +9 more
core  

Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Axatilimab, a monoclonal antibody targeting colony‐stimulating factor 1 (CSF‐1) receptor, is approved in the US for the treatment of chronic graft‐versus‐host disease (cGVHD) after failure of ≥2 lines of systemic therapy. In this study, the effects of antidrug antibody (ADA) status on the pharmacokinetics, pharmacodynamics, efficacy, and safety of ...
Yan‐ou Yang, Xing Liu, Breann Barker, Xuecheng Zhang, Peter Ordentlich   +4 more
wiley   +1 more source

Treatment-Free Remission in Ph+ ALL Without Allogeneic Stem Cell Transplantation: Current Evidence and Future Directions. [PDF]

Cancers (Basel)
Canichella M, Trawinska MM, Mazzone C, de Fabritiis P, Abruzzese E.   +4 more
europepmc   +1 more source

Does Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation Predict Treatment Failure in Children with Non-Malignant Disease?

, 2016
Young Bae Choi, Eun Sang Yi, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo   +5 more
openalex   +1 more source

Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis

Cytometry Part A, EarlyView.
ABSTRACT Myelofibrosis is a myeloproliferative neoplasm with potential to transform to acute myeloid leukemia. This evolution is unpredictable and current assays lack the sensitivity and applicability needed to predict this transformation. While population‐level data utilizing comprehensive genomic profiling can identify subgroups at higher risk of ...
Ruby M. Hamilton, Ryan J. Collinson, Henry Y. Hui, Zi Yun Ng, Hun S. Chuah, Malcolm Webb, Belinda B. Guo, Wendy N. Erber, Kathy A. Fuller   +8 more
wiley   +1 more source